Venetoclax-based salvage therapy as a bridge to transplant is feasible and effective in patients with relapsed/refractory AML

Abstract: The B-cell lymphoma 2 inhibitor venetoclax (VEN) in combination with hypomethylating agents has been approved for first-line treatment of patients with acute myeloid leukemia (AML) ineligible for intensive treatment. VEN-containing treatment strategies may also be effective in relapsed/ref...

Full description

Bibliographic Details
Published in:	Blood Advances
Main Authors:	Julia M. Unglaub, Richard F. Schlenk, Jan Moritz Middeke, Stefan W. Krause, Sabrina Kraus, Hermann Einsele, Michael Kramer, Sven Zukunft, Joseph Kauer, Simon Renders, Elena Katelari, Christoph Schliemann, Caroline Pabst, Thomas Luft, Peter Dreger, Christoph Röllig, Martin Bornhäuser, Carsten Müller-Tidow, Tim Sauer
Format:	Article
Language:	English
Published:	Elsevier 2025-01-01
Online Access:	http://www.sciencedirect.com/science/article/pii/S2473952924005585

Similar Items

PB2413: SALVAGE THERAPY WITH VENETOCLAX AND A HYPOMETHYLATING AGENT FOR PATIENTS WITH AML RELAPSE AFTER ALLOGENEIC STEM CELL TRANSPLANTATION
by: Inna Shaforostova, et al.
Published: (2023-08-01)

Age‐stratified machine learning identifies divergent prognostic significance of molecular alterations in AML
by: Jan‐Niklas Eckardt, et al.
Published: (2025-05-01)

UBTF tandem duplications are rare but recurrent alterations in adult AML and associated with younger age, myelodysplasia, and inferior outcome
by: Julia-Annabell Georgi, et al.
Published: (2023-05-01)

Venetoclax salvage therapy in relapsed/refractory multiple myeloma
by: Maximilian J. Steinhardt, et al.
Published: (2023-10-01)

S123: ACUTE MYELOID LEUKEMIA STEM CELL SUBTYPES DEFINED BY MUTATIONS AND DIFFERENTIATION STATE REGULATE APOPTOTIC DEPENDENCY AND CLINICAL RESPONSE TO VENETOCLAX.
by: Alexander Waclawiczek, et al.
Published: (2023-08-01)

PB1849: EARLY SALVAGE THERAPY WITH VENETOCLAX AND 10-DAY DECITABINE IS FEASIBLE AND SAFE IN REFRACTORY AML: RESULTS FROM 11 PATIENTS WITH EARLY INDUCTION FAILURE
by: Carla Borst, et al.
Published: (2023-08-01)

Venetoclax for AML: changing the treatment paradigm
by: Daniel A. Pollyea, et al.
Published: (2019-12-01)

P490: SNORNA-DERIVED RNAS (SDRNAS) ARE IMPORTANT DRIVERS OF LEUKEMOGENESIS AND LEUKEMIC MAINTENANCE IN AML
by: R. Zinz, et al.
Published: (2022-06-01)

Time from diagnosis to treatment has no impact on survival in newly diagnosed acute myeloid leukemia treated with venetoclax-based regimens
by: David Baden, et al.
Published: (2024-04-01)

P528: CAN MULTIPARAMETRIC FLOW CYTOMETRY OF PERIPHERAL BLOOD CHALLENGE BONE MARROW ANALYSES FOR DETECTION OF MEASURABLE RESIDUAL DISEASE IN PATIENTS WITH ACUTE MYELOID LEUKEMIA?
by: Jonas Schadt, et al.
Published: (2023-08-01)

P447: BCL2-INHIBITION TARGETS LEUKEMIC STEM CELLS IN ACUTE MYELOID LEUKEMIA INDEPENDENT OF MONOCYTIC BLAST POPULATIONS
by: S. Renders, et al.
Published: (2022-06-01)

MRD in Venetoclax-Based Treatment for AML: Does it Really Matter?
by: Massimo Bernardi, et al.
Published: (2022-07-01)

P454: VENETOCLAX AND GILTERITINIB SYNERGIZE IN FLT3 WILDTYPE ACUTE MYELOID LEUKEMIA BY SUPPRESSION OF MCL-1 VIA COMBINED AXL AND FLT3 TARGETING
by: C. Schmidt, et al.
Published: (2022-06-01)

P408: COMBINATORIAL BCL-2 FAMILY EXPRESSION IN ACUTE MYELOID LEUKEMIA STEM CELLS PREDICTS CLINICAL RESPONSE TO AZACITIDINE/VENETOCLAX
by: Simon Renders, et al.
Published: (2023-08-01)

Investigating resistance to 5-Azacytidine and Venetoclax in PDX models of MDS/AML
by: Petra Bašová, et al.
Published: (2025-01-01)

Prognostic significance of monocytic-like phenotype in patients with AML treated with venetoclax and azacytidine
by: Lin-Pierre Zhao, et al.
Published: (2025-07-01)

FOXM1-AKT Positive Regulation Loop Provides Venetoclax Resistance in AML
by: Mikhail S Chesnokov, et al.
Published: (2021-07-01)

P555: OLUTASIDENIB IN POST-VENETOCLAX PATIENTS WITH MUTANT IDH1 AML
by: Jorge Cortes, et al.
Published: (2023-08-01)

Long-term survival in a patient with primary refractory AML after salvage allogeneic hematopoietic transplantation and post-transplant localized irradiation and venetoclax maintenance: a case report
by: Yili Fan, et al.
Published: (2023-12-01)

Safety run-in and part 1 of GIMEMA AML1718: venetoclax combined with FLAI as induction treatment in non–low-risk AML
by: Giovanni Marconi, et al.
Published: (2025-05-01)

Venetoclax schedule in AML: 7 vs 14 vs 21 vs 28 days
by: Naseema Gangat, et al.
Published: (2025-04-01)

The association of FAT1 mutations with therapeutic outcomes in AML, especially in receiving venetoclax combination
by: Tao Wang, et al.
Published: (2025-03-01)

P534: AZACITIDINE PLUS VENETOCLAX FOR THE TREATMENT OF RELAPSED AND FIRST-LINE AML PATIENTS
by: S. Garciaz, et al.
Published: (2022-06-01)

Q-HAM: a multicenter upfront randomized phase II trial of quizartinib and high-dose Ara-C plus mitoxantrone in relapsed/refractory AML with FLT3-ITD
by: Sonia Jaramillo, et al.
Published: (2023-09-01)

(R)-WAC-224, a new anticancer quinolone, combined with venetoclax and azacitidine overcomes venetoclax-resistant AML through MCL-1 downregulation
by: Hiroshi Ureshino, et al.
Published: (2025-05-01)

Mimicking clinical trials with synthetic acute myeloid leukemia patients using generative artificial intelligence
by: Jan-Niklas Eckardt, et al.
Published: (2024-03-01)

Successful venetoclax salvage in the setting of refractory, dialysis-dependent multiple myeloma with t(11;14)
by: Dawn Swan, et al.
Published: (2020-03-01)

P053 | SURVEY OF THE VERO STUDY SITES FOR AML TREATMENT WITH VENETOCLAX PLUS AZACITIDINE IN ITALY
by: M.G. Della Porta, et al.
Published: (2025-09-01)

P073 | RETROSPECTIVE ANALYSIS OF INFECTIONS RELATED TO VENETOCLAX+AZACITIDINE REGIMEN IN ELDERLY AML PATIENTS
by: D. Kasmi, et al.
Published: (2025-09-01)

P488: SAFETY AND EFFICACY OF VENETOCLAX PLUS “7 + 3” CHEMOTHERAPY IN NEWLY DIAGNOSED AML
by: Ioannis Mantzaris, et al.
Published: (2023-08-01)

P564: HOMOHARRINGTONINE AND CYTARABINE COMBINED WITH VENETOCLAX (HAV) FOR ADULT PATIENTS WITH DE NOVO AML
by: Xiao-Hua Luo, et al.
Published: (2023-08-01)

Venetoclax Combined with Azacitidine and Homoharringtonine in Relapsed/Refractory AML: A Multicenter, Phase 2 Trial
by: Hua Jin, et al.
Published: (2023-04-01)

The Evolving Treatment Landscape of AML
by: Sabine Blum, et al.
Published: (2022-03-01)

The Evolving Treatment Landscape of AML
by: Sabine Blum, et al.
Published: (2022-03-01)

PB1790: LOOKING ‘BENEATH’ THE SURFACE: PROTEOMICS AND GLYCIPROTEOMICS REVEAL NOVEL TARGETS FOR CAR-T CELL THERAPIES IN ACUTE MYELOID LEUKEMIA (AML)
by: Josephine Brysting, et al.
Published: (2023-08-01)

DP022 | OUTPATIENT VS INPATIENT VENETOCLAX+AZACITIDINE REGIMEN IN ELDERLY AML: A RETROSPECTIVE ANALYSIS
by: D. Kasmi, et al.
Published: (2025-09-01)

PPARγ-induced upregulation of fatty acid metabolism confers resistance to venetoclax and decitabine therapy in AML
by: Kotoko Yamatani, et al.
Published: (2025-08-01)

A STAT3 DEGRADER DEMONSTRATES PRE-CLINICAL EFFICACY IN VENETOCLAX RESISTANT MDS & AML
by: A. Shastri, et al.
Published: (2024-01-01)

VENETOCLAX-BASED THERAPIES IN PEDIATRIC ADVANCED MDS AND RELAPSED/REFRACTORY AML: A MULTICENTER RETROSPECTIVE ANALYSIS
by: Riccardo Masetti, et al.
Published: (2023-12-01)

P419: IDENTIFICATION OF NOVEL THERAPEUTIC OPTIONS FOR VENETOCLAX-RESISTANT AML CELLS THROUGH DRUG REPURPOSING
by: A. Ladungova, et al.
Published: (2022-06-01)